Table 2.
Baseline characteristics of patients recruited for the validation phase of the study.
| Validation Phase | |
|---|---|
| Patient Demographics | Patients on 81 mg ASA (n = 40) |
| Mean (SD) | |
| Age (yrs) | 68 (11) |
| Platelet Count (108/mL) | 185.3 (48) |
| WBC (108/mL) | 6.8 (1.9) |
| HCT | 0.3832 (0.03) |
| Frequency (%) | |
| Sex (male) | 24 (60) |
| Hypertension | 27 (68) |
| Hyperlipidemia | 33 (83) |
| Diabetes | 20 (50) |
| Smoking | 29 (73) |
| CAD | 13 (33) |
| PAD | 22 (55) |
| Medications (Frequency, %) | |
| Statin | 34 (85) |
| ACEi/ARB | 20 (50) |
| B-blockers | 9 (23) |
Acetylsalicylic acid, ASA; white blood cells, WBC; hematocrit, HCT; angiotensin-converting enzyme inhibitors/angiotensin receptor blocker ACEi/Arb; coronary artery disease, CAD; peripheral arterial disease, PAD. Continuous variables are shown as means (and standard deviations). Categorical variables are shown as frequencies (%).